Anders Grubb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2454503/publications.pdf

Version: 2024-02-01

194 papers 15,499 citations

63 h-index 120 g-index

202 all docs $\begin{array}{c} 202 \\ \\ \text{docs citations} \end{array}$

202 times ranked 11229 citing authors

#	Article	IF	CITATIONS
1	Performance of creatinineâ€based equations to estimate glomerular filtration rate with a methodology adapted to the context of drug dosage adjustment. British Journal of Clinical Pharmacology, 2022, 88, 2118-2127.	2.4	24
2	Cystatin C-based equations for estimating glomerular filtration rate do not require race or sex coefficients. Scandinavian Journal of Clinical and Laboratory Investigation, 2022, 82, 162-166.	1.2	10
3	The Modified CKiD Study Estimated GFR Equations for Children and Young Adults Under 25 Years of Age: Performance in a European Multicenter Cohort. American Journal of Kidney Diseases, 2022, 80, 807-810.	1.9	12
4	Large difference but high correlation between creatinine and cystatin C estimated glomerular filtration rate in Mesoamerican sugarcane cutters. Occupational and Environmental Medicine, 2022, 79, 497-502.	2.8	3
5	Development and Validation of a Modified Full Age Spectrum Creatinine-Based Equation to Estimate Glomerular Filtration Rate. Annals of Internal Medicine, 2021, 174, 183-191.	3.9	157
6	Markers of renal function at admission and mortality in hip fracture patients - a single center prospective observational study. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 201-207.	1.2	7
7	Proteins linked to atherosclerosis and cell proliferation are associated with the shrunken pore syndrome in heart failure patients. Proteomics - Clinical Applications, 2021, 15, e2000089.	1.6	11
8	Glomerular filtration and shrunken pore syndrome in children and adults. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 2503-2508.	1.5	9
9	MO071PROTEINS LINKED TO ATHEROSCLEROSIS AND CELL PROLIFERATION ARE ASSOCIATED WITH SHRUNKEN PORE SYNDROME IN HEART FAILURE PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	O
10	MO131THE SHRUNKEN PORE SYNDROME IS ASSOCIATED WITH POOR PROGNOSIS AND LOWER QUALITY OF LIFE IN HEART FAILURE PATIENTS- THE HARVEST-MALM× STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
11	Multiple-Biomarker Panel Estimated GFR Is Not Optimal or Cost-Effective. American Journal of Kidney Diseases, 2021, 77, 823.	1.9	1
12	Potential relationship between eGFR _{cystatin C} /eGFR _{creatinine} â€ratio and glomerular basement membrane thickness in diabetic kidney disease. Physiological Reports, 2021, 9, e14939.	1.7	15
13	The Shrunken pore syndrome is associated with poor prognosis and lower quality of life in heart failure patients: the HARVESTâ€Malmö study. ESC Heart Failure, 2021, 8, 3577-3586.	3.1	13
14	New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. New England Journal of Medicine, 2021, 385, 1737-1749.	27.0	1,236
15	Cystatin C Plays a Sex-Dependent Detrimental Role in Experimental Autoimmune Encephalomyelitis. Cell Reports, 2020, 33, 108236.	6.4	15
16	Structural Characterization of Covalently Stabilized Human Cystatin C Oligomers. International Journal of Molecular Sciences, 2020, 21, 5860.	4.1	3
17	Prospects for improved glomerular filtration rate estimation based on creatinine—results from a transnational multicentre study. CKJ: Clinical Kidney Journal, 2020, 13, 674-683.	2.9	11
18	Shrunken pore syndrome and mortality: a cohort study of patients with measured GFR and known comorbidities. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80, 412-422.	1.2	40

#	Article	IF	Citations
19	Shrunken pore syndrome - a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options. Clinical Biochemistry, 2020, 83, 12-20.	1.9	42
20	A novel method for creatinine adjustment makes the revised Lund–Malmö GFR estimating equation applicable in children. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80, 456-463.	1.2	25
21	Performance of Indexed and Nonindexed Estimated GFR. American Journal of Kidney Diseases, 2020, 76, 446-449.	1.9	19
22	The domain swapping of human cystatin C induced by synchrotron radiation. Scientific Reports, 2019, 9, 8548.	3.3	13
23	CKD: A Call for an Age-Adapted Definition. Journal of the American Society of Nephrology: JASN, 2019, 30, 1785-1805.	6.1	198
24	Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins. Kidney International Reports, 2019, 4, 67-79.	0.8	43
25	The mortality increase in cardiac surgery patients associated with shrunken pore syndrome correlates with the eGFR _{cystatin C} /eGFR _{creatinine} -ratio. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 167-173.	1.2	30
26	Validation of standardized creatinine and cystatin C GFR estimating equations in a large multicentre European cohort of children. Pediatric Nephrology, 2019, 34, 1087-1098.	1.7	45
27	Synthesis and SAR Studies of Antibacterial Peptidyl Derivatives Based upon the Binding Site of Human Cystatin C. Protein and Peptide Letters, 2019, 26, 423-434.	0.9	0
28	The first step in creating national Chronic Kidney Disease (CKD) guidelines – a questionnaire. Biochemia Medica, 2019, 29, 441-470.	2.7	3
29	The Impact of the Glomerular Filtration Rate on the Human Plasma Proteome. Proteomics - Clinical Applications, 2018, 12, e1700067.	1.6	37
30	Comparison of glomerular filtration rate estimating equations derived from creatinine and cystatin C: validation in the Age, Gene/Environment Susceptibility-Reykjavik elderly cohort. Nephrology Dialysis Transplantation, 2018, 33, 1380-1388.	0.7	37
31	Cyclic trimer of human cystatin C, an amyloidogenic protein - molecular dynamics and experimental studies. Journal of Applied Physics, 2018, 123, 174701.	2.5	3
32	GFR estimation based on standardized creatinine and cystatin C: a European multicenter analysis in older adults. Clinical Chemistry and Laboratory Medicine, 2018, 56, 422-435.	2.3	34
33	Accuracy of GFR estimating equations in a large Swedish cohort: implications for radiologists in daily routine and research. Acta Radiologica, 2017, 58, 367-375.	1.1	7
34	Cystatin C peptidomimetic derivative with antimicrobial properties as a potential compound against wound infections. Bioorganic and Medicinal Chemistry, 2017, 25, 1431-1439.	3.0	7
35	Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors. Journal of Leukocyte Biology, 2017, 101, 1233-1243.	3.3	28
36	Accuracy diagrams: a novel way to illustrate uncertainty of estimated GFR. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 199-204.	1,2	8

#	Article	IF	Citations
37	Estimating glomerular filtration rate (GFR) in children. The average between a cystatin C- and a creatinine-based equation improves estimation of GFR in both children and adults and enables diagnosing Shrunken Pore Syndrome. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 338-344.	1.2	32
38	Overall conformation of covalently stabilized domain-swapped dimer of human cystatin C in solution. Nuclear Instruments & Methods in Physics Research B, 2017, 411, 136-140.	1.4	1
39	Measured glomerular filtration rate does not improve prediction of mortality by cystatin C and creatinine. Nephrology Dialysis Transplantation, 2017, 32, 663-670.	0.7	16
40	Accurate eGFR reporting for children without anthropometric data. Clinica Chimica Acta, 2017, 474, 38-43.	1.1	14
41	Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells. Oncotarget, 2017, 8, 73793-73809.	1.8	22
42	Cystatin C is Indispensable for Evaluation of Kidney Disease. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2017, 28, 268-276.	0.7	26
43	Shrunken Pore Syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 74-81.	1.2	53
44	The shrunken pore syndrome is associated with declined right ventricular systolic function in a heart failure population – the HARVEST study. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 568-574.	1.2	34
45	Estimating GFR prior to contrast medium examinations—what the radiologist needs to know!. European Radiology, 2016, 26, 425-435.	4.5	5
46	Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: ‰Shrunken pore syndrome'. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 333-340.	1.2	85
47	Accuracy of GFR estimating equations combining standardized cystatin C and creatinine assays: a cross-sectional study in Sweden. Clinical Chemistry and Laboratory Medicine, 2015, 53, 403-14.	2.3	75
48	Performance of GFR Estimating Equations Stratified by Measured or Estimated GFR: Implications for Interpretation. American Journal of Kidney Diseases, 2015, 66, 1107-1108.	1.9	13
49	Fertility Defects in Mice Expressing the L68Q Variant of Human Cystatin C. Journal of Biological Chemistry, 2014, 289, 7718-7729.	3.4	18
50	Two new types of assays to determine protein concentrations in biological fluids using mass spectrometry of intact proteins with cystatin C in spinal fluid as an example. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 546-554.	1.2	5
51	The revised Lund-Malm \tilde{A}^{\P} GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. Clinical Chemistry and Laboratory Medicine, 2014, 52, 815-24.	2.3	144
52	Generation of a New Cystatin C–Based Estimating Equation for Glomerular Filtration Rate by Use of 7 Assays Standardized to the International Calibrator. Clinical Chemistry, 2014, 60, 974-986.	3.2	248
53	Measuring GFR: A Systematic Review. American Journal of Kidney Diseases, 2014, 64, 411-424.	1.9	391
54	Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling. FASEB Journal, 2013, 27, 2687-2701.	0.5	32

#	Article	IF	Citations
55	Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. Journal of Neuroscience Methods, 2013, 215, 234-240.	2.5	47
56	Stabilization, Characterization, and Selective Removal of Cystatin C Amyloid Oligomers. Journal of Biological Chemistry, 2013, 288, 16438-16450.	3.4	20
57	Cathepsin B Degrades Amyloid- \hat{l}^2 in Mice Expressing Wild-type Human Amyloid Precursor Protein. Journal of Biological Chemistry, 2012, 287, 39834-39841.	3.4	93
58	Interaction of serum amyloid A with human cystatin Câ€"identification of binding sites. Journal of Molecular Recognition, 2012, 25, 513-524.	2.1	15
59	Improved estimation of glomerular filtration rate (GFR) by comparison of eGFR _{cystatin C} and eGFR _{creatinine} . Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 73-77.	1.2	75
60	Quantification of cystatin C by time-resolved fluorometry-based immunoassays. Journal of Immunological Methods, 2012, 378, 56-61.	1.4	2
61	High throughput testing of drug library substances and monoclonal antibodies for capacity to reduce formation of cystatin C dimers to identify candidates for treatment of hereditary cystatin C amyloid angiopathy. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 676-682.	1.2	8
62	Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 145-149.	1.2	72
63	Cystatin C influences the autoimmune but not inflammatory response to cartilage type II collagen leading to chronic arthritis development. Arthritis Research and Therapy, 2011, 13, R54.	3. 5	16
64	Cystatin C as a Biomarker in Kidney Disease. , 2011, , 291-312.		6
65	Cystatin C- and creatinine-based GFR-prediction equations for children and adults. Clinical Biochemistry, 2011, 44, 501-502.	1.9	3
66	The CKD-EPI and MDRD equations to estimate GFR. Validation in the Swedish Lund-Malmö Study cohort. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 129-138.	1.2	45
67	Revised equations for estimating glomerular filtration rate based on the Lund-Malmö Study cohort. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 232-239.	1.2	157
68	Crystal structure of human cystatinâ€fC stabilized against amyloid formation. FEBS Journal, 2010, 277, 1726-1737.	4.7	73
69	Dry-Reagent Double-Monoclonal Assay for Cystatin C. Clinical Chemistry, 2010, 56, 1424-1431.	3.2	8
70	First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1619-1621.	2.3	312
71	A new tool for predicting the probability of chronic kidney disease from a specific value of estimated GFR. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 327-333.	1.2	7
72	Cystatin C Rescues Degenerating Neurons in a Cystatin B-Knockout Mouse Model of Progressive Myoclonus Epilepsy. American Journal of Pathology, 2010, 177, 2256-2267.	3.8	51

#	Article	IF	CITATIONS
73	Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: Simultaneous use of cystatin C- and creatinine-based GFR-prediction equations, clinical data and an internal quality check. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 65-70.	1.2	87
74	Performance evaluation of a turbidimetric cystatin C assay on different high-throughput platforms. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 347-353.	1.2	22
75	Induction of Autophagy by Cystatin C: A Mechanism That Protects Murine Primary Cortical Neurons and Neuronal Cell Lines. PLoS ONE, 2010, 5, e9819.	2.5	104
76	Cystatin C Deficiency Promotes Epidermal Dysplasia in K14-HPV16 Transgenic Mice. PLoS ONE, 2010, 5, e13973.	2.5	24
77	Production of Cystatin C Wild Type and Stabilized Mutants. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2010, 20, 166-70.	0.7	O
78	Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients. Blood Pressure, 2009, 18, 196-203.	1.5	3
79	DEMONSTRATION OF SEPARATE RECEPTORS FOR HUMAN IgA AND IgG IN GROUP A STREPTOCOCCI TYPE. Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology, 2009, 88C, 77-82.	0.0	12
80	Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatric Nephrology, 2009, 24, 67-76.	1.7	406
81	Variability in diagnostic accuracy can be estimated using simple population weighting. Journal of Clinical Epidemiology, 2009, 62, 54-57.	5.0	11
82	Validation of a new plasma cystatin C-based formula and the Modification of Diet in Renal Disease creatinine-based formula for determination of glomerular filtration rate. Scandinavian Journal of Urology and Nephrology, 2009, 43, 242-249.	1.4	14
83	Different equations to combine creatinine and cystatin C to predict GFR. Arithmetic mean of existing equations performs as well as complex combinations. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 619-627.	1.2	41
84	The Dispersion of Water Proton Spin-Lattice Relaxation Rates in Aqueous Human Protein HC (α) Tj ETQq0	0 0 rgBT /	Overlock 10 T
85	Governing the monomer-dimer ratio of human cystatin c by single amino acid substitution in the hinge region Acta Biochimica Polonica, 2009, 56, .	0.5	30
86	Governing the monomer-dimer ratio of human cystatin c by single amino acid substitution in the hinge region. Acta Biochimica Polonica, 2009, 56, 455-63.	0.5	13
87	Cystatin C-Cathepsin B Axis Regulates Amyloid Beta Levels and Associated Neuronal Deficits in an Animal Model of Alzheimer's Disease. Neuron, 2008, 60, 247-257.	8.1	196
88	Elevated infection parameters and infection symptoms predict an acute coronary event. Therapeutic Advances in Cardiovascular Disease, 2008, 2, 419-424.	2.1	19
89	The Lund–Malmö creatinineâ€based glomerular filtration rate prediction equation for adults also performs well in children. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 568-576.	1.2	36
90	Different elimination patterns of βâ€trace protein, β2â€microglobulin and cystatin C in haemodialysis, haemodiafiltration and haemofiltration. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 685-691.	1.2	29

#	Article	IF	Citations
91	Fibrillogenic Oligomers of Human Cystatin C Are Formed by Propagated Domain Swapping. Journal of Biological Chemistry, 2007, 282, 18318-18326.	3.4	112
92	Cystatin C modulates cerebral β-amyloidosis. Nature Genetics, 2007, 39, 1437-1439.	21.4	151
93	Cystatin C binds serum amyloid A, downregulating its cytokine-generating properties. Journal of Rheumatology, 2007, 34, 1293-301.	2.0	21
94	Checking the conformational stability of cystatin C and its L68Q variant by molecular dynamics studies: Why is the L68Q variant amyloidogenic?. Journal of Structural Biology, 2006, 154, 68-78.	2.8	26
95	The Role of Cystatin C in Cerebral Amyloid Angiopathy and Stroke: Cell Biology and Animal Models. Brain Pathology, 2006, 16, 60-70.	4.1	92
96	Lowered levels of serum albumin and HDLâ€cholesterol in children with a recent mild infection. Annals of Medicine, 2006, 38, 154-160.	3.8	14
97	Notable Steps in Obtaining Improved Estimates for Glomerular Filtration Rate. Clinical Chemistry, 2006, 52, 169-170.	3.2	4
98	Errors in the Assessment of Estimated Glomerular Filtration Rate: Reply. Clinical Chemistry, 2006, 52, 154-155.	3.2	2
99	Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors. Journal of Biological Chemistry, 2006, 281, 6020-6029.	3.4	229
100	Cystatin C as a marker of GFR—history, indications, and future research. Clinical Biochemistry, 2005, 38, 1-8.	1.9	606
101	Cystatin C modulates neurodegeneration and neurogenesis following status epilepticus in mouse. Neurobiology of Disease, 2005, 20, 241-253.	4.4	59
102	In Search of Selective Inhibitors of Cysteine Protease, Cathepsin K. International Journal of Peptide Research and Therapeutics, 2005, 11, 203-209.	1.9	2
103	3D domain-swapped human cystatin C with amyloidlike intermolecular \hat{l}^2 -sheets. Proteins: Structure, Function and Bioinformatics, 2005, 61, 570-578.	2.6	93
104	Lack of the Cysteine Protease Inhibitor Cystatin C Promotes Atherosclerosis in Apolipoprotein E–Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2151-2156.	2.4	103
105	Absence of the protease inhibitor cystatin C in inflammatory cells results in larger plaque area in plaque regression of apoE-deficient mice. Atherosclerosis, 2005, 180, 45-53.	0.8	35
106	Simple Cystatin C–Based Prediction Equations for Glomerular Filtration Rate Compared with the Modification of Diet in Renal Disease Prediction Equation for Adults and the Schwartz and the Counahan–Barratt Prediction Equations for Children. Clinical Chemistry, 2005, 51, 1420-1431.	3.2	413
107	Cystatin C Deficiency Increases Elastic Lamina Degradation and Aortic Dilatation in Apolipoprotein E–Null Mice. Circulation Research, 2005, 96, 368-375.	4.5	144
108	Elevated Plasma Levels of Nt-proBNP in Patients With Type 2 Diabetes Without Overt Cardiovascular Disease. Diabetes Care, 2004, 27, 1929-1935.	8.6	95

#	Article	IF	CITATIONS
109	Cysteine proteases in Langerhans cells limits presentation of cartilage derived type II collagen for autoreactive T cells. International Immunology, 2004, 16, 717-726.	4.0	12
110	Prevention of Domain Swapping Inhibits Dimerization and Amyloid Fibril Formation of Cystatin C. Journal of Biological Chemistry, 2004, 279, 24236-24245.	3.4	102
111	Osteoclastogenesis is decreased by cysteine proteinase inhibitors. Bone, 2004, 34, 412-424.	2.9	46
112	Domain Swapping in N-truncated Human Cystatin C. Journal of Molecular Biology, 2004, 341, 151-160.	4.2	71
113	Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scandinavian Journal of Clinical and Laboratory Investigation, 2004, 64, 25-30.	1.2	342
114	New antimicrobial cystatin Câ€based peptide active against gramâ€positive bacterial pathogens, including methicillinâ€resistant <i>Staphylococcus aureus</i> and multiresistant coagulaseâ€negative staphylococci. Apmis, 2003, 111, 1004-1010.	2.0	23
115	Serum cystatin C reflects glomerular endotheliosis in normal, hypertensive and preâ€eclamptic pregnancies. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 825-830.	2.3	65
116	The Protease Inhibitor Cystatin C Is Differentially Expressed among Dendritic Cell Populations, but Does Not Control Antigen Presentation. Journal of Immunology, 2003, 171, 5003-5011.	0.8	74
117	Serum Cystatin C Is a More Sensitive and More Accurate Marker of Glomerular Filtration Rate than Enzymatic Measurements of Creatinine in Renal Transplantation. Nephron Physiology, 2003, 94, p19-p27.	1.2	67
118	Glomerular filtration rate dependence of sieving of albumin and some neutral proteins in rat kidneys. American Journal of Physiology - Renal Physiology, 2003, 284, F1226-F1234.	2.7	118
119	Azapeptides Structurally Based upon Inhibitory Sites of Cystatins as Potent and Selective Inhibitors of Cysteine Proteases. Journal of Medicinal Chemistry, 2002, 45, 4202-4211.	6.4	43
120	The cerebral hemorrhage-producing cystatin C variant (L68Q) in extracellular fluids. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2001, 8, 1-10.	3.0	58
121	Urine excretion of protein HC in proteinuric glomerular diseases correlates to urine IgG but not to albuminuria. Kidney International, 2001, 60, 1904-1909.	5.2	44
122	Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nature Structural Biology, 2001, 8, 316-320.	9.7	353
123	Low-Level Cadmium Exposure and Osteoporosis. Journal of Bone and Mineral Research, 2000, 15, 1579-1586.	2.8	226
124	Hereditary cystatin C amyloid angiopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 70-79.	3.0	82
125	Low level exposure to cadmium and early kidney damage: the OSCAR study. Occupational and Environmental Medicine, 2000, 57, 668-672.	2.8	313
126	FGF-2-Responsive Neural Stem Cell Proliferation Requires CCg, a Novel Autocrine/Paracrine Cofactor. Neuron, 2000, 28, 385-397.	8.1	295

#	Article	IF	Citations
127	Synthesis and antibacterial properties of peptidyl derivatives and cyclopeptides structurally based upon the inhibitory centre of human cystatin C: Dissociation of antiproteolytic and antibacterial effects. Apmis, 2000, 108, 473-481.	2.0	1
128	Synthesis and antibacterial properties of peptidyl derivatives and cyclopeptides structurally based upon the inhibitory centre of human cystatin C. Dissociation of antiproteolytic and antibacterial effectsNote. Apmis, 2000, 108, 473-481.	2.0	18
129	Rheumatoid Arthritis – A Gene Transfer Disease. Experimental and Clinical Immunogenetics, 1999, 16, 1-7.	1.2	11
130	Expression of a selenomethionyl derivative and preliminary crystallographic studies of human cystatin C. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 1939-1942.	2.5	28
131	Biomarkers of nephrotoxicity in children environmentally exposed to lead in Poland. Journal of Environmental Medicine, 1999, 1, 33-38.	0.2	8
132	Cystatin C deficiency in human atherosclerosis and aortic aneurysms. Journal of Clinical Investigation, 1999, 104, 1191-1197.	8.2	397
133	First international reference preparation for individual proteins in urine. Clinical Biochemistry, 1998, 31, 467-474.	1.9	9
134	Affinity screening for weak monoclonal antibodies. Journal of Immunological Methods, 1998, 220, 19-24.	1.4	12
135	Proteinuria selectivity index based upon $\hat{l}\pm 2$ -macroglobulin or IgM is superior to the IgG based index in differentiating glomerular diseases. Kidney International, 1998, 54, 2098-2105.	5.2	42
136	Structural Basis for Different Inhibitory Specificities of Human Cystatins C and Dâ€. Biochemistry, 1998, 37, 4071-4079.	2.5	62
137	The Increase of Plasma Homocysteine Concentrations with Age Is Partly due to the Deterioration of Renal Function as Determined by Plasma Cystatin C. Clinical Chemistry and Laboratory Medicine, 1998, 36, 175-178.	2.3	133
138	Cystatin F Is a Glycosylated Human Low Molecular Weight Cysteine Proteinase Inhibitor. Journal of Biological Chemistry, 1998, 273, 24797-24804.	3.4	133
139	Renal impairment after hip or knee arthroplasty: Urinary excretion of protein markers studied in 59 patients. Acta Orthopaedica, 1997, 68, 34-40.	1.4	20
140	Cystatin E is a Novel Human Cysteine Proteinase Inhibitor with Structural Resemblance to Family 2 Cystatins. Journal of Biological Chemistry, 1997, 272, 10853-10858.	3.4	140
141	Apolipoprotein-E Genotyping in Alzheimer's Disease and Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 1997, 8, 240-243.	1.5	56
142	Long-term Stability of Albumin, Protein HC, Immunoglobulin G, \hat{l}^2 - and \hat{l}^3 -chain-immunoreactivity, Orosomucoid and $\hat{l}\pm 1$ -antitrypsin in Urine Stored at -20 \hat{A}° C. Scandinavian Journal of Urology and Nephrology, 1997, 31, 67-71.	1.4	61
143	Albumin Adducts in Plasma From Workers Exposed to Toluene Diisocyanate. Analyst, The, 1997, 122, 151-154.	3.5	41
144	Massive glycation of protein HC, a low molecular weight lipocalin, in non-diabetic individuals. FEBS Letters, 1997, 416, 276-280.	2.8	2

#	Article	IF	CITATIONS
145	No Effect of Diclofenac on the Pharmacokinetics of Cloxacillin. Basic and Clinical Pharmacology and Toxicology, 1997, 81, 26-30.	0.0	8
146	Lead Binding to δâ€Aminolevulinic Acid Dehydratase (ALAD) in Human Erythrocytes. Basic and Clinical Pharmacology and Toxicology, 1997, 81, 153-158.	0.0	155
147	Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1996, 114, 303-311.	1.6	58
148	Application of liquid chromatography–inductively coupled plasma mass spectrometry to the study of protein-bound lead in human erythrocytes. Journal of Analytical Atomic Spectrometry, 1996, 11, 735-738.	3.0	37
149	Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus. Cancer Chemotherapy and Pharmacology, 1996, 39, 25-33.	2.3	29
150	Spectroscopic characterization by photodiode array detection of human urinary and amniotic protein HC subpopulations fractionated by anion-exchange and size-exclusion high-performance liquid chromatography. Journal of Chromatography A, 1996, 719, 149-157.	3.7	11
151	Renal handling of radiolabelled human cystatin C in the rat. Scandinavian Journal of Clinical and Laboratory Investigation, 1996, 56, 409-414.	1.2	413
152	Measurement of oxygen consumption and heat production in plasma from uremic patients on chronic dialysis treatment. Thermochimica Acta, 1995, 251, 173-176.	2.7	1
153	Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney International, 1995, 47, 312-318.	5.2	540
154	Structural Basis for the Biological Specificity of Cystatin C. Journal of Biological Chemistry, 1995, 270, 5115-5121.	3.4	109
155	Cloning and sequencing of a cDNA encoding ratd-dopachrome tautomerase. FEBS Letters, 1995, 373, 203-206.	2.8	52
156	DNA sequences specific for Caucasian G3m(b) and (g) allotypes: allotyping at the genomic level. Immunogenetics, 1994, 39, 187-193.	2.4	83
157	Interaction between streptococcal protein Arp and different molecular forms of human immunoglobulin A. Molecular Immunology, 1994, 31, 393-400.	2.2	10
158	A sequence variation in the human cystatin D gene resulting in an amino acid (Cys/Arg) polymorphism at the protein level. Human Genetics, 1993, 90, 668-9.	3.8	17
159	An Ala/Thr variation in the coding region of the human cystatin C gene (CST3) detected as a Sstll polymorphism. Human Genetics, 1993, 92, 206-7.	3.8	22
160	A Rapid Enzyme-Linked Immunosorbent Assay for Serum Amyloid a Using Sequence-Specific Antibodies. Annals of Clinical Biochemistry, 1993, 30, 278-286.	1.6	15
161	Recent developments in the chemistry and biology of cystatins. , 1993, , 243-246.		1
162	Demonstration of sequence variations in the promoter region of the human cystatin C gene. Biological Chemistry Hoppe-Seyler, 1992, 373, 471-476.	1.4	6

#	Article	IF	CITATIONS
163	Cystatin C Based Peptidyl Diazomethanes as Cysteine Proteinase Inhibitors: Influence of the Peptidyl Chain Length. Journal of Enzyme Inhibition and Medicinal Chemistry, 1992, 6, 113-123.	0.5	49
164	Hereditary cystatin C amyloid angiopathy: identification of the disease-causing mutation and specific diagnosis by polymerase chain reaction based analysis. Human Genetics, 1992, 89, 377-80.	3.8	71
165	A novel mutation in the ?-protein coding region of the amyloid ?-protein precursor (APP) gene. Human Genetics, 1992, 89, 580-2.	3.8	26
166	Human cystatin C, a cysteine proteinase inhibitor, inhibits bone resorption in vitro stimulated by parathyroid hormone and parathyroid hormone-related peptide of malignancy. Journal of Bone and Mineral Research, 1992, 7, 433-440.	2.8	79
167	HCâ€igA antibodies of different specificities are normally present in serum: quantitation by ELISA and relationship to the major Ig classes. Apmis, 1990, 98, 249-254.	2.0	0
168	Identification of Cystatin C, a Cysteine Proteinase Inhibitor, as a Major Secretory Product of Human Alveolar Macrophages <i>In Vitro</i> . The American Review of Respiratory Disease, 1990, 141, 698-705.	2.9	84
169	Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor. Nature, 1989, 337, 385-386.	27.8	213
170	Isolation and characterization of a tumor necrosis factor binding protein from urine. European Journal of Haematology, 1989, 42, 270-275.	2,2	234
171	Efficient production of native, biologically active human cystatin C byEscherichia coli. FEBS Letters, 1988, 236, 14-18.	2.8	168
172	Safer proteinase treatment of sciatica A biochemical preview of chymopapain inhibitors. Acta Orthopaedica, 1988, 59, 63-65.	1.4	8
173	Identification of retinol as one of the protein HC chromophores. Biochemical and Biophysical Research Communications, 1988, 155, 1424-1429.	2.1	21
174	Effects of Plasmapheresis on the Plasma Concentration of Proteins Used to Monitor the Disease Process in Multiple Myeloma. Acta Medica Scandinavica, 1988, 223, 263-267.	0.0	1
175	A tumor necrosis factor binding protein is present in human biological fluids. European Journal of Haematology, 1988, 41, 414-419.	2.2	106
176	Molecular cloning and sequence analysis of cDNA coding for the precursor of the human cysteine proteinase inhibitor cystatin C. FEBS Letters, 1987, 216, 229-233.	2.8	164
177	THE PREVALENCE OF RENAL AMYLOIDOSIS OF THE AAâ€₹YPE IN A SERIES OF 1,158 CONSECUTIVE AUTOPSIES. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1987, 95A, 297-302.	0.3	4
178	DEMONSTRATION AND CLASSIFICATION OF AMYLOIDOSIS IN NEEDLE BIOPSIES OF THE KIDNEYS, WITH SPECIAL REFERENCE TO AMYLOIDOSIS OF THE AAâ€TYPE. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1987, 95A, 357-363.	0.3	5
179	Production of an amino acid sequence-specific antiserum against human amyloid A (AA) and serum amyloid A (SAA) protein. Scandinavian Journal of Clinical and Laboratory Investigation, 1987, 47, 619-626.	1.2	9
180	The blood serum concentration of cystatin C (\hat{l}^3 -trace) as a measure of the glomerular filtration rate. Scandinavian Journal of Clinical and Laboratory Investigation, 1985, 45, 97-101.	1.2	308

#	Article	IF	CITATIONS
181	A sensitive and rapid enzyme-linked immunosorbent assay using monoclonal antibodies for simultaneous quantitation of free and IgA-complexed protein HC. Journal of Immunological Methods, 1985, 82, 101-110.	1.4	19
182	Serum Concentration of Cystatin C, Factor D and <i>β</i> 2â€Microglobulin as a Measure of Glomerular Filtration Rate. Acta Medica Scandinavica, 1985, 218, 499-503.	0.0	244
183	Feasibility of Extracorporeal Onâ€Line Largeâ€Scale Plasma Adsorptions on Protein Aâ€Sepharose Columns in Cancer Patients. Artificial Organs, 1984, 8, 72-81.	1.9	16
184	The disulphide bridges of human cystatin C (\hat{l}^3 -trace) and chicken cystatin. FEBS Letters, 1984, 170, 370-374.	2.8	51
185	The place of human \hat{I}^3 -trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochemical and Biophysical Research Communications, 1984, 120, 631-636.	2.1	282
186	Abnormal Metabolism of \hat{I}^3 -Trace Alkaline Microprotein. New England Journal of Medicine, 1984, 311, 1547-1549.	27.0	147
187	Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 3024-3027.	7.1	294
188	Isolation and Some Properties of an IgG Fc-Binding Protein from Group A Streptococci Type 15. International Archives of Allergy and Immunology, 1982, 67, 369-376.	2.1	69
189	Production of protein HC by human fetal liver explants. Biochimica Et Biophysica Acta - General Subjects, 1978, 542, 506-514.	2.4	40
190	Nonâ€Secretory or Lowâ€Secretory Myeloma with Intracellular Kappa Chains. Acta Medica Scandinavica, 1978, 204, 445-451.	0.0	26
191	The amino-terminal sequence of human protein HC. FEBS Letters, 1976, 70, 239-240.	2.8	14
192	Preparation of electroendosmosis-free agarose gel and exemplification of its use in crossed immunoelectrophoresis. Analytical Biochemistry, 1973, 55, 582-592.	2.4	24
193	Quantitative determination of the distribution of the specific antibodies of antisera subjected to gel electrophoresis. Immunochemistry, 1972, 9, 635-645.	1.2	3
194	Intracellular Distribution of Lipase in Comparison to Trypsinogen, Amylase and Immediately Measureable Trypsin Inhibitor(s) in the Rat Pancreas. Acta Physiologica Scandinavica, 1969, 75, 139-148.	2.2	23